MUSIi001-A-2 BioVector®低免疫原性B2M和CIITA双基因敲除人诱导多能干细胞系iPSC

BioVector®

• 基因编辑： 使用 CRISPR/Cas9 技术进行的双基因敲除。

• 敲除靶点：

  • B2M（β2-微球蛋白）：敲除后导致 HLA I 类分子表面表达缺失。

  • CIITA（MHC II 类转录激活因子）：敲除后导致 HLA II 类分子表面表达缺失。

  
  

• 功能： 通过消除 HLA I 类和 II 类分子的表达，该细胞系能够逃避受体免疫系统的识别，从而降低异体移植时的免疫排斥风险。

• 来源： 衍生自 MUSIi001-A-1（单敲除 B2M），最初的亲本细胞（MUSIi001-A）取自一名 33 岁健康女性的剖宫产瘢痕成纤维细胞。

BioVector®MUSIi001-A-2 is a human induced pluripotent stem cell (iPSC) line genetically engineered to be hypoimmunogenic for use in allogeneic cell therapy research.

• Genetic Modifications: It is a dual-gene knockout line created using CRISPR/Cas9 technology. It features biallelic disruptions of the B2M (Beta-2-Microglobulin) and CIITA (Class II Major Histocompatibility Complex Transactivator) genes.

• Functionality: These modifications eliminate the expression of both HLA Class I and HLA Class II molecules on the cell surface. This makes the cells "invisible" to certain parts of the immune system, reducing the risk of graft rejection in allogeneic (off-the-shelf) therapies.

• Parental Line: It was derived from the MUSIi001-A-1 line (a B2M-only knockout), which itself originated from the wild-type MUSIi001-A line. The original parental cells were fibroblasts from a 33-year-old healthy female.

• Pluripotency: The line maintains typical iPSC characteristics, including the ability to differentiate into all three embryonic germ layers.

Supplier生产商：

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

E-mail:BioVector@163.com

电话:400-800-2947

工作QQ/微信同号:1843439339

网址 www.biovector.net